News

01. Nov 2018

OMEICOS Therapeutics Closes €17m Series C Financing

...to Advance Lead Candidate

Open Article

01. November 2018 OMEICOS Therapeutics Closes €17m Series C Financing

Berlin, Germany, and Boston, MA, USA, November 2, 2018 - OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the closing of a EUR 17 million (approx. USD 19.5 million) Series C financing led by new investor Forbion. Existing investors Vesalius Biocapital II S.A. SICAR, Remiges BioPharma Fund, SMS group GmbH, KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG and The Falck Revocable Trust participated as well. The proceeds from this round will finance PROMISE-AF, a placebo controlled, double-blinded, randomized, dose finding Phase II study on OMT-28 in maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation. Additionally, OMEICOS will continue to drive the expansion of its pipeline into novel indications including ophthalmology, led by its US-based subsidiary OMEICOS Ophthalmics.

"This financing arrives in a particularly exciting time for the OMEICOS team as we accelerate plans to initiate our Phase II study of OMT-28, OMEICOS' novel safe rhythm stabilizer developed for patients with atrial fibrillation. The investment of Forbion confirms the excellent work of the entire team and supports our ambitious plans in atrial fibrillation and other indications," commented Robert Fischer, MD, CEO/CSO of OMEICOS Therapeutics.

Holger Reithinger, Ph.D. General Partner at Forbion added: "We've been following the OMEICOS story for some time and are very positive about the progress. The unique concept of a novel treatment for atrial fibrillation together with the excellent safety data of OMT-28 convinced us to invest and support the future growth of the company."

Christian Schneider, Ph.D. Managing Partner at Vesalius Biocapital commented: "The addition of Forbion is another consequent step in the successful development of OMEICOS. The shareholders highly welcome Forbion's commitment to join forces in order to accelerate the company's development pipeline in indications with high unmet medical need."

OMEICOS is developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. The compounds are synthetic analogs of naturally occurring, but metabolically unstable, metabolites of omega-3 fatty acids that can activate anti-arrhythmic, cardio protective and anti-inflammatory pathways. OMEICOS' first-in-class small molecules can be administered orally and have shown improved biological activity and pharmacokinetic properties compared to their natural counterparts. Atrial fibrillation is the most common type of heart arrhythmia affecting an estimated 33.5 million people worldwide. Incidence is expected to increase over the next decade as life expectancy increases. The disease is associated with significant health risks and current therapies have limited efficacy and safety.

OMEICOS Ophthalmics was established in Boston, MA, USA in August 2017 to focus on a clinical development program for OMEICOS' ophthalmological drug indications. OMEICOS' compounds are currently in preclinical development for macular edema disease, including wet age-related macular degeneration (AMD) and diabetic retinopathy. New treatments for wet AMD are needed to reduce the burden of repeated, frequent injections of therapeutics into the eye, and to offer more convenient routes of administration.

About OMEICOS

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS' small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. OMEICOS' technology is based on ground-breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies' founders, Dr. Wolf-Hagen Schunck, Prof. John. R. Falck, Prof. Dominik Mueller and Dr. Robert Fischer. The companies' research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com

Contacts:

OMEICOS Therapeutics GmbH
Dr. Robert Fischer, CEO, CSO
Phone: +49 (0) 30 9489 4810
E-Mail: r.fischer@omeicos.com
www.omeicos.com

Media requests:

MacDougall Biomedical Communications
Mario Brkulj or Amanda Houlihan
Main: +49 89 2424 3494 or +1 781-235-3060
E-Mail: omeicos@macbiocom.com

About IBB Beteiligungsgesellschaft

IBB Beteiligungsgesellschaft (www.ibb-bet.de) provides venture capital to innovative Berlin-based companies and has established itself as a market leader in the field of early stage financing in Germany. The funds are used primarily for the development and market launch of innovative products or services, as well as for business concepts of creative industries. Currently two of the funds managed by the IBB Beteiligungsgesellschaft are in the investment phase, the VC Fonds Technologie Berlin II with a fund size of 60 million euros and the VC Fonds Kreativwirtschaft Berlin II with a fund size of 40 million euros. Both VC funds are financed by means of the Investitionsbank Berlin (IBB) and the European Fund for Regional Development (EFRE) administered by the State Berlin. Since 1997 the IBB Beteiligungsgesellschaft, in consortia with partners, has made 1.33 billion euros available to creative and technology-orientated companies; thereof, the portion invested by IBB Beteiligungsgesellschaft itself, as lead, co-lead or co-investor, was approximately 184 million euros.

Contact:

Ute Mercker
IBB Beteiligungsgesellschaft mbH
Bundesallee 210
10719 Berlin

Tel.: +49 (0) 30 2125 3201
Fax: +49 (0) 30 2125 3202
E-Mail: venture@ibb-bet.de
Web: www.ibb-bet.de

29. October 2018 Contentflow Raises €2 Million in Seed Funding

Cloud Based Streaming SaaS Platform Gets Backing from Speedinvest, VC Fonds Technologie Berlin (IBB Beteiligungsgesellschaft), Betaworks, Akatuski Entertainment Technology Fund & Notable Angel Investors

Berlin, October 29, 2018 – Contentflow, a cloud-based SaaS solution for all facets of live-streaming, announced that it has raised a €2 million seed round investment from leading venture capital firms and angel investors. Participating in the round are: Speedinvest (lead), VC Fonds Technologie Berline, Betaworks, and Japanese Akatsuki Entertainment Technology Fund as well as other notable angels.

With their in-house streaming engine, Contentflow enables its clients to live-stream content to all current social media platforms including Instagram, Facebook and Twitch as well as directly to websites. Targeted at business clients as an easier and faster way to monetize content, Contentflow provides browser-based live, on-the-fly editing and rendering on all devices. Current clients include ARD Aktuell, Online Marketing Rockstars (OMR) and FUNKE media group. In the US, the Electronic Sports League (ESL) is currently testing the Contentflow platform as a better way to reach their audiences worldwide.

While Hamburg based Next Media Accelerator supported development last year, the three founders are now expanding the circle of shareholders and have big plans. This round of funding will be used to continue to evolve the platform and increase expansion in the US market.

"This newly acquired capital will help us accelerate our international expansion," said Managing Director and co-founder Sebastian Serafin. “Contentflow only began operations New York City 6 months ago and we have already acquired our first US client."

Mr. Serafin continued, “Thanks to the support of NMA and business angels including Jens Schumann and Martin Dräger and the hard work of our entire team in Berlin, Hamburg, and New York, Contentflow has developed a market-ready technology and gained noteworthy clients in just one year! “

"Contentflow convinced us right from the start and our customers were delighted, so we are very pleased that the indicators for the young company point towards continued growth," says Nico Lumma, Managing Partner at Next Media Accelerator.

"Contentflow marks the next step in the democratization of live-streaming. As an experienced investor in this field (bitmovin, hitbox), the team quickly won us over with its comprehensive understanding of the needs of users and its passion for the topic," says Daniel Keiper-Knorr from Speedinvest. "Contentflow has already demonstrated significant traction and a promising product roadmap in an exciting market. We look forward to joining the committed founding team and international investors in the software market for live-streaming," says Tobias Schimmelpfennig, Investment Manager at IBB Beteiligungsgesellschaft.

Exciting new functionality recently announced

Several weeks ago, the company announced that together with Deutsche Welle it will receive funding from the Google Digital News Innovation Fund (DNI). This will allow Contentflow’s live-streams to provide additional data via automated face and object recognition which could lead to new advertising formats, among other things. "We believe that live-streaming will continue to evolve the way media is consumed and Contentflow is dedicated to raising everyone’s expectations of what is possible with our technology,” explains co-founder Gregor Landwehr.

Contact:

Tobias Schimmelpfennig
IBB Beteiligungsgesellschaft mbH
Bundesallee 210
10719 Berlin

Phone: +49 (0) 30 2125 3201
E-Mail: venture@ibb-bet.de
Web: http://www.ibb-bet.dewww.ibb-bet.de

07. August 2018 Utility-in-a-box software provider Lumenaza raises EUR 2.5 million

Utility-in-a-box software provider Lumenaza raises EUR 2.5 million to accelerate growth

Berlin, 7-Aug-18. The software company Lumenaza announced today the successful closure of a EUR 2.5 million financing round. With this round E.ON joined as investor of the Berlin-based company. Both existing investors, EnBW New Ventures and VC Fonds Technologie Berlin managed by IBB Beteiligungsgesellschaft mbH, participated significantly as well. The funds will be used to accelerate Lumenaza’s growth, to strengthen its technical leadership in innovative energy services, and to continue with its internationalization.

The investment highlights the increasing demand for transparency and personalization by energy customers, as well as the trend towards building communities and delivering tailor-made solutions to its participants. Lumenaza’s scalable and flexible software connects renewable energy producers, from small rooftop PV systems up to large wind farms, with energy consumers and enables precise billing. This makes it possible to provide customers with advanced solutions such as community energy, local and regional energy or even nation-wide innovative tariff concepts including time-based tariffs, flat tariffs and peer-to-peer energy solutions.

Christian Chudoba, founder and CEO of Lumenaza, stated: “We are delighted to see the trust from existing and new investors in our company. Having now two of Europe’s leading utilities on our investors’ board brings substantial expertise and will help us to further innovate and grow across Europe. With this additional investment our software will become even more powerful to support innovative utilities and other energy market players such as hardware manufacturers to offer highly-personalized solutions to their customers based on distributed, clean and affordable energy sources.”

“We are convinced by Lumenaza’s vision and business model. We already had the pleasure to successfully work together with Lumenaza for the EU-funded local smart grid system in Simris, Sweden, demonstrating how local and sustainable energy communities can be realized already today,” said Dr. Philipp Ulbrich, Vice President Innovation Scouting and Co-Investments of E.ON.

Crispin Leick, Managing Director of EnBW New Ventures, added: “We like the team, we like the business model, we are happy to continue to support the strong growth of Lumenaza. The investment is part of our strategy to develop and commercialize attractive business models.”

“We are highly pleased with Lumenaza’s performance. The company has recognized the need for software in the energy market early-on. We are looking forward to seeing Lumenaza grow further and accompany the team in this journey”, commented Stephan Schulze, Investment Director of IBB Beteiligungsgesellschaft.

Lumenaza started in 2013 to connect and intelligently control producers and consumers of renewable energy. Today the modular software platform works literally as a “utility-in-a-box”, enabling any company to participate in the energy market at different levels, including the possibility to become a full innovative and digital utility. Lumenaza has realized exciting projects such as regional power, energy communities, tenant electricity, and data visualization for its customers, including three of Germany's four largest energy suppliers, a world's leading home energy storage manufacturer and several regional utilities.

About Lumenaza

Lumenaza is the software provider for the new, decentralized and digitized energy world. The software can offer virtually all the functions that are needed in the energy market in a modular form as a “utility-in-a-box”. The company is able to monitor renewable power plants, include power from large and small generation plants, manage balancing groups, and make real-time energy management data available to all market participants. The green electricity can be resold directly to the end customer. Lumenaza makes it possible to connect and intelligently manage all participants in the new energy world in a single digital marketplace, thereby addressing utilities, new players and producers alike. Lumenaza thus provides a peer-to-peer energy market.

www.lumenaza.de/en

Contact:

Jan Bohnerth
Tel: +49 (0)176 921 84 991
Mail: jan.bohnerth@lumenaza.de

03. July 2018 HIGH MOBILITY Raises € 3 Million

HIGH MOBILITY Raises € 3 Million To Bring Standardised Connected Car API To Global Developer Ecosystem

Berlin, 3rd July 2018: Berlin-based developer platform for connected cars HIGH MOBILITY has secured a capital increase round of € 3 million, reaffirming the current investors’ continued trust in the pioneering startup and the founders’ vision to connect the auto industry to a global ecosystem of developers. Following this vote of confidence, and on the back of innovative collaborations with Porsche and Mercedes-Benz in the last 12 months, HIGH MOBILITY will focus its efforts on bringing its unique developer platform including the powerful Auto API to an even wider developer community.

“HIGH MOBILITY is on its course to become the gold standard for the connected car API,” said CEO and co-founder Risto Vahtra. “In an era where software and services are increasingly defining a carmaker’s success, we are dedicated to building the best platform for connected car app development and bringing that platform to a global developer ecosystem.”

Led by a group of private investors with deep understandings of the industry headed by Fabian von Kuenheim and the Berlin-based venture capital firm IBB Beteiligungs-gesellschaft, the investment will be used to accelerate the work towards providing app developers with real car data through a standardised car API.

Building on the success with existing OEMs and customers like Mercedes-Benz and Porsche, the company will launch further projects with major players in the auto industry, drive its global expansion, and accelerate work with existing customers over the course of the next 12 months.

“We have been invested in HIGH MOBILITY since the early days. It fits perfectly our suite of other investments in the car industry, focused on Autonomous Driving and Connected Car as well as Advanced Emission Control systems. HIGH MOBILITY is the seldom exception where a startup delivers its innovations within budget and timeframe and exceeds revenue predictions at the same time,” added the lead investor Fabian von Kuenheim. “It is a joy working with such an open-minded, flexible and visionary team in shaping the future of the car industry.” 

HIGH MOBILITY, founded in 2013 by Risto Vahtra and CTO Kevin Valdek, successfully closed its seed funding round in early 2016 with a 7-digit investment, again headed by Fabian von Kuenheim and the Berlin-based venture capital firm IBB Beteiligungsgesellschaft. The next significant milestone for the company will be the launch of its expanded connected car app development platform in the second half of July 2018 which will include dedicated developer workspaces from major car manufacturers and car emulators for specific vehicle models.  

The company currently boasts close to 2000 connected car app developers from over 50 countries who are actively engaged in the platform, many of whom have also built projects in simulation pilots with carmakers in direct response to the industry’s fast-changing attitude towards connectivity. No longer sticklers for tradition, carmakers are now actively responding to driver demands for improved app ecosystems and services. HIGH MOBILITY acts as the bridge between the global developer community and major car manufacturers who are seeking to find and maintain a strong footing in the digital sphere. 

HIGH MOBILITY is a unique developer platform for the building and testing of connected car applications and services. An alumnus of Startupbootcamp and Startup Autobahn, the platform recreates the experience of working with real-world connected vehicles in a simulated environment through the use of an innovative car emulator, access to SDKs, tools and documentation as well as over 200 APIs. The company currently has offices in Berlin, Germany and in Tallinn, Estonia. 

Contacts for press enquiries: 

High-Mobility GmbH
Kadi-Ingrid Lilles
Marketing Manager
kadi@high-mobility.com
+49 157 820 33436
www.high-mobility.com

Contact IBB Beteiligungsgesellschaft:

Stephan Schulze
IBB Beteiligungsgesellschaft
Bundesallee 210
10719 Berlin
Tel: +49 (0)30 2125 3201
Mail: venture@ibb-bet.de 

20. June 2018 Blinkist raises $18.8 million Series C round

Blinkist raises $18.8 million Series C round led by Insight Venture Partners to become the leading destination for lifelong learners across the world 

The micro-learning app and platform, used by over 6 million people globally, condenses non-fiction titles into 15-minute audio and text digests

Berlin, 20 June 2018 - Blinkist, the micro-learning app and platform providing personal and professional development, today announces it has raised a Series C round of $18.8 million, led by Insight Venture Partners, with participation from existing investors Greycroft, IBB Bet, and e.ventures, to expand its global operations.

The company, which boasts an international network of over 6 million users, will use the funding to grow its Berlin-based team, establish Country Managers for individual markets, scale its international customer base, and continue to improve a product which is increasingly popular with time-poor, and information-hungry young professionals. Blinkist is currently available in English and German, but is planning to use the investment to strengthen its footprint across the globe and increase localised efforts in core markets, with plans to offer the service in additional languages. 

Blinkist CEO and co-founder Holger Seim comments: "We've experienced exciting growth over the past five years, but as a company, we are only just beginning to scratch the surface when it comes to the international opportunities that lie ahead of us. The problem that we are solving for millions of people across the world is one that we see every day; the significant gap between people's desire to read and learn more, and the actual time they spend doing so.” 

Holger continues, "The new investment from Insight Venture Partners will help us to realise our company's potential and establish Blinkist as a leading destination for lifelong learning. We’ll use the funding to deliver a broader set of topics and formats to our ever-growing and diversifying user base, in addition to localising the Blinkist experience as we move into new markets.”

One of Berlin’s fastest-growing startups since its foundation in 2012, Blinkist offers users audio and text-based topline insights from best-selling, as well as undiscovered (and often under-acknowledged), non-fiction books. These 15-minute digests, or "books-in-blinks", feature the key ideas extracted from over 2,500 non-fiction books, in multiple genres including entrepreneurship, politics, science, psychology, investment, and parenting. Each title is carefully selected by a dedicated editorial team, providing authors with discoverability and access to an eager, carefully targeted audience.

“As a concept and an investment opportunity, Blinkist offers something genuinely unique. The company presents an exciting model which is defining and spearheading a whole new category of self-development.” comments Harley Miller, Vice President at Insight Venture Partners. “We only want to work with the brightest and most ambitious teams, and we know that Blinkist and its founders share our vision for making a positive, global impact.”

Nicolas Wittenborn, Vice President at Insight Venture Partners adds: “The Blinkist founders have identified and created a product that is truly transformative, and one that harnesses the growing thirst for short-form, mobile-first information. With audio content continuing to boom, and as the huge scale opportunities for Blinkist open up, we are excited to reaffirm our commitment to their growth at this pivotal moment in their journey.”

The Series C funding brings Blinkist’s total investment to $35 million. Joining the board from Insight Venture Partners are Harley Miller and Nicolas Wittenborn, while Markus Witte, CEO and co-founder of language learning app Babbel, joins as an independent board member.

Blinkist presents a disruptive model that is increasingly being embraced by a publishing industry eager to engage with digitally-savvy millennials and young professionals seeking continued learning and self-improvement, yet untouched by traditional book promotion models (and certainly never reached by reviews of specialist non-fiction titles).

A 2018 report by the International Federation of Periodical Publishers found that millennial readers are the biggest receivers and supporters of subscription-based information; a market which traditional publishers can tap into through services like Blinkist. 

Blinkist can be downloaded and used for free, with users getting access to one free book-in-blinks which changes on a daily basis. Through a Premium membership (UK - £59.99/year or £11.49/month; US $79.99/year or $12.99/month), subscribers can browse and enjoy over 2,500 titles subdivided into the following primary categories: Entrepreneurship & Small Business, Politics & Society, Marketing & Sales, Science, Health & Fitness, personal Growth & Self-Improvement, Economics, Biography & History, Communication & Social Skills, Corporate Culture, management & Leadership, Motivation & Inspiration, Money & Investments, Psychology, Productivity & Time Management, Sex & Relationships, Technology & the Future, Mindfulness & Happiness, and Parenting. 

25. July 2017 Berlin‘s machtfit GmbH secures growth financing round led by Seventure Partners

A leader in corporate health solutions in Germany, Berlin‘s machtfit GmbH secures growth financing round led by Seventure Partners 

Berlin, July 25, 2017 – machtfit closes EUR 2.2 million Series B round led by Seventure Partners, a Paris-based venture and growth investor in healthcare, microbiome and nutri-tion. Existing investors Dr. Becker Klinikgruppe, IBB Beteiligungsgesellschaft and PHS Capital also participated in the investment round. Since its market entry in 2011, machtfit’s corporate health solution has become the leading platform for corporate health in Germany. The funding will be used to expand machtfit’s market position and product offering. 

machtfit offers an online platform and smartphone-app for corporate health solutions. The platform enables the employers to offer regional fitness and well-being activities to their employees contrib-uting to maintenance and promotion of healthier lifestyle and wellbeing. To date, machtfit works with over 100 companies, including TOTAL Deutschland, Vattenfall Europe, Lufthansa Bombardier Aviation Services, DB Vertrieb GmbH and Gazprom Germania GmbH. machtfit has continually expanded its market leadership and developed the platform into the leading solution for digital cor-porate health promotion. machtfit partners with over 4.500 health providers in Germany, including 

Bodychange, Holmes Place, fitbit, Freeletics and Weight Watchers. The digital platform informs and engages employees to make better health decisions, guides them to the program, product or provider that best fits their needs, and enables them to book the offer with a few clicks, no matter where they are or work. Additionally, it supports companies internal HR processes through digitali-zation.

In connection with the financing round, Oxana Kukhaneva, Seventure Partners, joins the compa-ny’s Board of Directors.

Isabelle de Cremoux, CEO and Managing Partner at Seventure Partners, says: „The field of health and wellbeing has the potential to benefit hugely from digital technology innovation. The current investment strengthens machtfit’s pole position to embrace and succeed in the evolving landscape of preventive healthcare and wellbeing in Europe.”

Daniel Steffen, Investment Manager at IBB Beteiligungsgesellschaft comments on the investment round: „The corporate health market is a growing market, the newly issued prevention act has added significant momentum – and machtfit is perfectly positioned to capitalize on that dynamic.”

Stephen Seuntjens, Partner at PHS Capital responds: „PHS is proud to be associated with and a supporter of machtfit!  We are impressed with the progress they have made in serving one of digital health’s frontiers, corporate health, and becoming a platform leader in Germany as well as with some of the world’s leading Corporations.”

Philippe Bopp, CEO and Founder of machtfit GmbH says: „The newly raised investment will help us grow faster and continually improve our health platform. We thank Seventure Partners and our existing investors for the trust in our mission and are looking forward to working together.”

Dr. Petra Becker of Dr. Becker Klinikgruppe says, when asked about the current state of the indus-try: „Many modern employers have already realized that corporate health promotion is a necessity these days. Yet, there are very few user-friendly offers that reach more than just a tiny fraction of employees”. She adds: „thanks to a wide range of offers including regional gym-passes, certified online-stress-coachings or apps like Freeletics and Weight Watchers, combined with the digital nature of the product, machtfit reaches significantly more employees than other corporate health services”.   

About IBB Beteiligungsgesellschaft
IBB Beteiligungsgesellschaft (www.ibb-bet.de [1]) provides venture capital to innovative Berlin-based companies and has established itself as a market leader in the field of early stage financing in Germany. The funds are used primarily for the development and market launch of innovative products or services, as well as for business concepts of creative industries. Currently two of the funds managed by the IBB Beteiligungsgesellschaft are in the investment phase, the VC Fonds Technologie Berlin II with a fund size of 60 million euros and the VC Fonds Kreativwirtschaft Berlin II with a fund size of 40 million euros. Both VC funds are financed by means of the Investitionsbank Berlin (IBB) and the European Fund for Regional Development (EFRE) administered by the State Berlin. Since 1997 the IBB Beteiligungsgesellschaft, in consortia with partners, has made 1.25 billion euros available to creative and technology-orientated companies; thereof, the portion invested by IBB Beteiligungsgesellschaft itself, as lead, co-lead or co-investor, was approximately 173 million euros.

Daniel Steffen
Bundesallee 210
10719 Berlin
Tel: 030/2125 3201
Mail: venture@ibb-bet.de
Internet: www.ibb-bet.de

 

01. March 2017 OMEICOS Announces First Closing of Series B Financing Round

OMEICOS Announces First Closing of €8.3 Million Series B Financing Round and the Initiation of Phase 1 Clinical Trial

Financing Provides Runway Beyond Completion of First-in-man Trial with Lead Compound OMT-28 for Treatment of Atrial Fibrillation


Berlin, Germany, March 1, 2017 — OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, today announced the first closing of a Series B financing round of €8.3 million and the initiation of a Phase 1 clinical trial with lead compound OMT-28 for the treatment of atrial fibrillation. The financing was led by Vesalius Biocapital II S.A. SICAR and SMS Company Group, along with existing investors KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG (HTGF), The Falck Revocable Trust, Ascenion GmbH and members of the management team. The funding will be used to support the newly initiated clinical program and to further leverage the therapeutic potential of the technology.

In addition to the financing, OMEICOS today announced the dosing of the first subject in the first-in-human clinical study for its lead candidate, OMT-28. The goal of the study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of OMT-28 in healthy volunteers. The randomized, double-blind, placebo-controlled Phase 1 study is being conducted in a single center in Germany and aims to enroll up to 100 subjects.

“The successful closing of the Series B financing round in combination with the initiation of the first clinical trial with our lead compound, OMT-28, marks the beginning of a new stage of corporate development for OMEICOS,” said Dr. Robert Fischer, CSO and co-founder of OMEICOS. “We are grateful for the ongoing support of our investors and anticipate this financing to fully fund the company throughout the duration of the Phase 1 clinical study, which will set the stage for a swift transition into a subsequent Phase 2 trial.”

“We believe in the potential of OMEICOS’ distinctive small molecules to treat atrial fibrillation and other inflammatory and cardiovascular diseases,” said Vesalius Biocapital’s Dr. Christian Schneider. “We look forward to seeing progress with the Phase 1 clinical trial and are pleased to continue and strengthen our financial investment in the company.”

OMEICOS’ lead compound, OMT-28, is a stable synthetic small molecule analog of the natural omega-3 fatty acid metabolite 17,18-EEQ, which has a structure optimized to provide high efficacy, safety and oral bioavailability. OMT-28 has already proven its anti-arrhythmic and cardioprotective potential in different in vivo experimental models. OMEICOS' synthetic analogs of omega-3 fatty acid epoxides are currently focused on cardiovascular diseases, although they have the potential to be applied across a wide range of diseases.

 

More information on the trial (Eudra-CT 2016-003445-28) will be provided via the European Union Clinical Trials Register.

About Atrial Fibrillation

Atrial fibrillation (AF) is the most common cardiac arrhythmia in humans. More than 30 million patients are affected worldwide and this number is increasing by 2% per year due to the aging population. AF is characterized by an irregular heart rhythm originating from the heart’s upper chambers, resulting in inefficient blood pumping. AF leads to a significant reduction in quality of life, increases the risk of stroke, raises the risk of heart failure and doubles the risk of death. Marketed anti-arrhythmic drugs have limited efficacy and often severe adverse effects, which together with the huge number of affected patients accounts for a high unmet medical need for a safe and efficacious medical treatment of AF.

 

About OMEICOS

OMEICOS Therapeutics is a spin-off company from the Max Delbrueck Center for Molecular Medicine (MDC) in Berlin. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat inflammatory, cardiovascular and other diseases. Epoxyeicosanoids, as a newly described class of bioactive lipid mediators, activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. OMEICOS’ technology is based on ground-breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders, Dr. Wolf-Hagen Schunck, Prof. John. R. Falck, Prof. Dominik Müller and Dr. Robert Fischer. The companies’ research activities are supported by a grant from the German Ministry of Education and Research (BMBF). www.omeicos.com

Contact:
OMEICOS Therapeutics GmbH
Dr. Ulrich Dauer, Chief Executive Officer and Managing Director
Dr. Robert Fischer, Chief Scientific Officer and Managing Director
Phone: +49 (0) 30 9489 4810
E-Mail: u.dauer@omeicos.com, r.fischer@omeicos.com
www.omeicos.com

Media requests:
MacDougall Biomedical Communications
Gretchen Schweitzer or Mario Brkulj
Phone: +49 (0) 89 2423 3494 or +49 175 5010575
E-Mail: mbrkulj@macbiocom.com

About IBB Beteiligungsgesellschaft

IBB Beteiligungsgesellschaft (www.ibb-bet.de) provides venture capital to innovative Berlin-based companies and has established itself as a market leader in the field of early stage financing in Germany. The funds are used primarily for the development and market launch of innovative products or services, as well as for business concepts of creative industries. Currently two of the funds managed by the IBB Beteiligungsgesellschaft are in the investment phase, the VC Fonds Technologie Berlin II with a fund size of 60 million euros and the VC Fonds Kreativwirtschaft Berlin II with a fund size of 40 million euros. Both VC funds are financed by means of the Investitionsbank Berlin (IBB) and the European Fund for Regional Development (EFRE) administered by the State Berlin. Since 1997 the IBB Beteiligungsgesellschaft, in consortia with partners, has made 1.25 billion euros available to creative and technology-orientated companies; thereof, the portion invested by IBB Beteiligungsgesellschaft itself, as lead, co-lead or co-investor, was approximately 173 million euros.


Contact:
Ute Mercker
IBB Beteiligungsgesellschaft
Bundesallee 210
10719 Berlin

Tel: +49 (0)30 2125 3201
Mail: venture@ibb-bet.de

26. January 2017 Dalia Raises $7m to Build "Global Insights Engine"

Dalia Raises $7m to Build "Global Insights Engine"

Berlin and London, 26th January 2017 – Dalia – the company that generates real-time market and opinion data from a global network of smartphone users – today announces that it has raised $7m in a Series A round led by Balderton Capital, with participation from existing investors Wellington Partners and IBB-Bet. 

Harnessing the app economy and machine learning, the Berlin-headquartered startup is building a global insights and information engine that distributes millions of micro surveys to gather and analyze real time data on consumer attitudes, public opinion and market trends. Since launching in 2013, Dalia has generated over a billion answers from people spread across 96 different countries on topics ranging from brand perception to macroeconomic sentiment.

As the $68bn global market and opinion research industry faces increased pressure to improve the quality of data-collection, the explosive growth in smartphone ownership worldwide provides fresh channels to reach audiences for high-quality insights. Dalia combines advanced data science and analytics with real-time targeting and attribution technologies to generate insights from global audiences at  unprecedented scale, quality and speed. 

From fine-grain to mass scale.

“From fine-grain, industry-specific data on, for example, yoghurt consumption in Mexico to large scale data-sets that can be used as ‘early-warning systems’ for housing bubbles or political instability, we equip our partners with the ability to understand the global trends and behaviors that shape the world around them,” says CEO Nico Jaspers. “Through our technology, we have the potential to reach over one billion people and give a voice to public opinion and consumer attitudes on a truly global scale.” 

The company’s customers include some of the world’s leading research agencies and organizations, including Nielsen, Ipsos and Kantar/WPP, as well as world-renowned universities, think tanks and NGOs, such as UNICEF, Stanford University, the Bertelsmann Foundation and the European Council on Foreign Relations.

Dalia plans to use the funding to invest heavily in data science, engineering and machine learning to further expand its real time analytics and attribution capacities. It is actively recruiting engineers, data scientists, as well as product and marketing specialists.

“Dalia has developed very rapidly and 2016 was our second consecutive year of revenue growth in excess of 500%,” says Nico Jaspers. “With Balderton Capital partnering with us, we are now extremely well-placed for the next phase of our growth.”

Balderton Capital’s Suranga Chandratillake adds: “Dalia’s unique ability to gather and sift insights, and to determine what people are thinking right across the world at any given moment, offers businesses and organizations huge competitive advantage, enabling them to act ahead of the curve rather than respond to events. We are delighted to be working alongside Nico and the team, as they help clients unlock value from data that would otherwise be out of reach.”

About IBB Beteiligungsgesellschaft 
IBB Beteiligungsgesellschaft (www.ibb-bet.de) provides venture capital to innovative Berlin-based companies and has established itself as a market leader in the field of early stage financing in Germany. The funds are used primarily for the development and market launch of innovative products or services, as well as for business concepts of creative industries. Currently two of the funds managed by the IBB Beteiligungsgesellschaft are in the investment phase, the VC Fonds Technologie Berlin II with a fund size of 60 million euros and the VC Fonds Kreativwirtschaft Berlin II with a fund size of 40 million euros. Both VC funds are financed by means of the Investitionsbank Berlin (IBB) and the European Fund for Regional Development (EFRE) administered by the State Berlin. Since 1997 the IBB Beteiligungsgesellschaft, in consortia with partners, has made 1.25 billion euros available to creative and technology-orientated companies; thereof, the portion invested by IBB Beteiligungsgesellschaft itself, as lead, co-lead or co-investor, was approximately 173 million euros.

Contact:
Clemens Kabel
IBB Beteiligungsgesellschaft
Bundesallee 210
10719 Berlin
Tel: +49 (0)30 2125 3201
Mail: venture@ibb-bet.de

About Dalia 
Founded in 2013 and headquartered in Berlin, Dalia is a fast-growing technology startup focused on giving research agencies, brands, consultancies, academia, public institutions and other organisations access to high-quality market and opinion data at a global scale. Harnessing the app economy and combining advanced data science with real-time targeting and attribution technologies, Dalia’s insights engine distributes millions of micro surveys worldwide to gather and analyze real time data on consumer attitudes, public opinion and market trends.

Backed by some of Europe’s leading venture capital firms, including Balderton Capital, Wellington Partners, IBB-Bet and WestTech Ventures, Dalia is the the proud winner of several industry, technology and data awards, including the 2015 IIeX Competition for the "most innovative startup in Europe" in the market research and consumer insights space. Since launching, Dalia has generated over a billion answers from people spread across 96 countries. The resulting data is cited in over 2,000 news articles globally, including in leading news journals such as The Economist, Le Monde, The Guardian, South China Morning Post, El Pais, Corriere della Serra, Vice Magazine, Politico, The Washington Post, and Der Spiegel. Discover more at www.daliaresearch.com

About Balderton Capital
Balderton Capital is one of the largest venture capital firms in Europe, focused on investing in the best European technology companies at Series A. Based in London, the firm manages $2.3bn. Since 2000, Balderton has invested in over 100 companies, principally across Europe. Notable investments include Talend (open-source data integration provider, went public on Nasdaq in 2016); Magic Pony Technologies (acquired by Twitter in 2016); NaturalMotion (the mobile gaming developer, sold to Zynga in 2014); Betfair (the online betting exchange, 2010 IPO; LOVEFiLM (the home entertainment subscription service, sold to Amazon in 2011); MySQL, (the open-source database software, sold to Sun Microsystems in 2008); and YOOX Group (the online retailer of leading fashion brands, IPO in 2009). The current portfolio includes companies such as 3D Hubs, Citymapper, Kobalt Music, Prodigy Finance, Qubit, Scytl, ROLI, Talend, and The Hut Group. 

14. September 2016 Transamerica Ventures and IBB Bet jointly invest in fairr.de

Transamerica Ventures and IBB Beteiligungsgesellschaft jointly invest in fairr.de

fairr.de raises Series A funding from Aegon-owned venture capital firm Transamerica Ventures and VC Fonds Technologie Berlin managed by IBB Beteiligungsgesellschaft. Saving Global-founders Tamaz Georgadze and Frank Freund also participated in the round, along with other industry insiders and business angels.

Berlin, 14 September 2016 – "These investments underline our role as the fastest growing pension provider in Germany and facilitate further execution of our strategy. In the coming months we will continue strengthening our team, developing our corporate pensions platform and boosting awareness of our award winning private pension products," says founder and CEO Jens Jennissen.

Clemens Kabel, investment director with IBB Beteiligungsgesellschaft, explains the investment rationale for VC Fonds Technologie: "We have closely observed the Fintech scene over the years and now have, for the first time, committed funds to an investment in this area. We found the consumer friendly product design, which has been independently confirmed in numerous tests, and the strong technological platform absolutely convincing. On this basis, fairr.de has the potential to further expand its role as a front-runner in the pension area."

“Fairr.de is the only Insurtech focused on state-sponsored savings plans. The team has a deep product knowledge and understanding of the needs of German pension savers. Everything is in place at fairr.de to develop high quality pension products for fair prices for consumers that will become the market standard," adds Marco Keim, global board member of Aegon.

Dr. Alexander Kihm, co-founder and head of product development clarifies: "We operate in a market full of red tape, which is complicated, but far too important to be left to traditional providers with obsolete sales structures and questionable incentives. At the same time, we demonstrate that disruption is also possible by cooperating with progressive banking and insurance partners."

Fairr.de GmbH was founded in November 2013 and has been financed by business angels. The founders also secured a place in the ProSiebenSat.1 Accelerator program receiving start-up financing and mentoring as well as an advertising budget of 500,000 euros.

More about fairr.de and the team: www.fairr.de/about-fairr/

Online newsroom: www.fairr.de/presse/

About Fairr.de GmbH

The founders of fairr.de are dedicated to developing efficient and customer-friendly retirement solutions.

For retail customers, fairr.de designs and offers state-subsidised savings plans in collaboration with Sutor Bank and myLife Lebensversicherung AG. The offering combines customer-friendly pricing, scientific investment management and guaranteed annuity rates and is unmatched in the German market. Fairr.de also cuts out expensive brokers and sales agents and does not charge sales commissions. Instead it sells its products online and cooperates with independent advisors.

To corporate customers fairr.de offers an online platform on which employers can establish and manage standardized and legally secure corporate pension schemes. The solution integrates robust processes, real time actuarial calculations and a graphic risk management interface into an intuitive front end. Fairr.de supports on-balance-sheet-, investment fund-, and individual life insurance based pensions and offers optional occupational disability insurance without the need for individual medical checks. Employees have access to individual portals where relevant pension information is up to date and intuitively presented.

Press Contact: Alexander Hinz | +49 (0)30 94413188 | presse@fairr.de | www.fairr.de/presse 

About Transamerica Ventures

Transamerica Ventures is the global venture arm of leading life insurance and asset management companies Transamerica and Aegon. Launched in early 2014 to help Transamerica and Aegon leverage innovation through a dedicated investment fund, Transamerica Ventures invests in startups developing technologies in the insurtech, fintech and enterprise software sectors and has offices in New York City and The Hague, The Netherlands. For more information, please visit www.transamericaventures.com.

Do you have questions?